IJSER Home >> Journal >> IJSER
International Journal of Scientific and Engineering Research
ISSN Online 2229-5518
ISSN Print: 2229-5518 11    
Website: http://www.ijser.org
scirp IJSER >> Volume 3,Issue 11,November 2012
A Review on Obesity and its Management[
Full Text(PDF, )  PP.958-966  
Author(s)
Md. Yaqub Khan*, Poonam Gupta, Bipin Bihari , Aparna Misra, Ashish Pathak, Vikas Kumar Verma 
KEYWORDS
Anorectic drugs, Anti-obesity properties , Appetite suppression, Genetic factors, Hypertension, Hyperlipidemia, Hypercholesterolemia, Obesity.
ABSTRACT
Obesity may be considered a chronic pathological condition resulting from complex interactions between cultural, psychological and genetic factors. During the past 30-40 years, a markedly increased emphasis on its control has, in part, resulted from evide
References
[1] WHO 2000 p.6

[2] Adams JP, Murphy PG (July 2000)."Obesity in anaesthesia and intensive care". Br J Anaesth 85 (1): 91– 108.doi:10.1093/bja/85.1.91. PMID10927998.

[3] Sturm R (July 2007)."Increases in morbid obesity in the USA: 2000–2005". Public Health 121 (7): 492–6.doi:10.1016/j. puhe.2007.01.006. PMC 2864630.PMID 17399752.

[4] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study".Lancet 364 (9438): 937– 52. doi:10.1016/S0140-6736(04)17018- 9. PMID 15364185.

[5] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study".Lancet 364 (9438): 937– 52. doi:10.1016/S0140-6736(04)17018-9. PMID 15364185.

[6] Haslam DW, James WP (2005). "Obesity". Lancet 366 (9492): 1197–209. doi:10.1016/S0140-6736(05)67483-1.PMID 16198769.

[7] Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. (2004). "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study".Lancet 364 (9438): 937– 52. doi:10.1016/S0140-6736(04)17018-9. PMID 15364185.

[8] Yosipovitch G, DeVore A, Dawn A (June 2007). "Obesity and the skin: skin physiology and skin manifestations of obesity". J. Am. Acad. Dermatol. 56 (6): 901–16; quiz 917– 20.doi:10.1016/j.jaad.2006.12.004. PMID 17504714

[9] Yosipovitch G, DeVore A, Dawn A (June 2007). "Obesity and the skin: skin physiology and skin manifestations of obesity". J. Am. Acad. Dermatol. 56 (6): 901–16; quiz 917– 20.doi:10.1016/j.jaad.2006.12.004. PMID 17504714

[10] WIN – Publication – Prescription Medications for the Treatment of Obesity". National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). National Institutes of Health. Archived from the original on 13 January 2009. Retrieved 14 January 2009.

[11] Anti-obesity drug no magic bullet". Canadian Broadcasting Corporation. 2 January 2007. Retrieved 19 September 2008.

[12] Pool, Robert (2001). Fat: Fighting the Obesity Epidemic. Oxford, UK: Oxford University Press. ISBN 0-19-511853-7.

[13] Royal college of Physicians of London.Clinical management of overweight and obese patients with particular reference to the use of drugs.London:RCP,1998.

[14] National Institutes of Health(NIH),National Heart,Lung and Blood Institute(NLLBI).Clinical gidelines on the identification, evaluation and treatment of overweight and obesity: the evidence report.Washington: US Government Press,1998.

[15] Fazekas, J.F. et al. (1959) Comparative effectiveness of phenylpropanolamine and dextro amphetamine on weight reduction J.AM. Med. Assoc. 170,1018-1021

[16] Asher,W.L. (1972) Mortality rate in patients receiving ‘diet pills’. Curr. Ther. Res. Clin. Exp. 14,525-539

[17] Pi-sunyer,X.et al.(1982) C-terminal octapeptide of cholecystokinin decreases food intake in obese men.Physiol.Behav.29,627-630

[18] Wynne,K. et al. (2006) Oxytomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial.Int.J.Obes(Lond.) 30,1729-1736

[19] Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review.. Arch Intern Med. 2004;164994-1003 PubMed

[20] Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials..Int J Obes Relat Metab Disord. 2002;26262-73 PubMed

[21] Boozer C, Daly P, Homel P, Solomon J, Blanchard D, Nasser J, Strauss R, Meredith T(2002). "Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial". Int J Obes Relat Metab Disord 26 (5): 593–604.doi:10.1038/sj.ijo.0802023.PMID 12032741.

[22] Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J. et al. A low- carbohydrate as compared with a low-fat diet in severe obesity.. N Engl J Med. 2003;3482074-81 PubMed

[23] Goldstein DJ. Beneficial health effects of modest weight loss.. Int JObesRelat Metab Disord 1992;16397-415 PubMed

[24] Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long- term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study.. Obes Res. 2001;9188-95 PubMed

[25] Sturm R (July 2007)."Increases in morbid obesity in the USA: 2000–2005". Public Health 121 (7): 492– 6.doi:10.1016/j.puhe.2007.01.006. PMC 2864630.PMID 17399752

[26] Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial.. JAMA. 2003;2891820-5 Pub Med

[27] Ephedra information from Memorial Sloan-Kettering Cancer Center. Retrieved 11 April 2007. Sturm R (July 2007)."Increases in morbid obesity in the USA: 2000–2005" Public Health 121 (7): 492– 6.doi:10.1016/j.puhe.2007.01.006. PMC 2864630.PMID 17399752

[28] Haslam DW, James WP (2005). "Obesity". Lancet 366 (9492): 1197–209. doi: 10.1016/S0140- 6736(05)67483-1 .PMID 16198769. [29] Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 4:1083–1095, 2005

[30] Boozer C, Daly P, Homel P, Solomon J, Blanchard D, Nasser J, Strauss R, Meredith T(2002). "Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial". Int J Obes Relat Metab Disord 26 (5): 593–604.doi:10.1038/sj.ijo.0802023.PMID 12032741.

[31] Medicines Control Agency statement on European legal action relating to anorectic agents. www.mca.gov.uk/whatsnew/whatsnew_2002.htm#2002

[32] Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up.. Obes Surg. 2000;10233-9 PubMed

[33] Karlsson J, Sjostrom L, Sullivan M. Swedish obese subjects (SOS)—an intervention study of obesity. Two-year followup of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity..Int J Obes Relat Metab Disord. 1998;22113-26 PubMed

[34] Karlsson J, Sjostrom L, Sullivan M. Swedish obese subjects (SOS)—an intervention study of obesity. Two-year followup of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity..Int J Obes Relat Metab Disord. 1998;22113-26 PubMed

[35] Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension.. Hypertension. 2000;3620-5 PubMed

[36] Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up.. Obes Surg. 2000;10233-9 PubMed

[37] Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States..JAMA. 2001;2861195-200 PubMed

[38] Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 4:1083–1095,2005

[39] Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ (February 2007). "Obesity and thrombosis". Eur J Vasc Endovasc Surg 33 (2): 223–33.doi:10.1016/j.ejvs.2006.10.006. PMID 17185009.

[40] McElroy,S.L.et al.(2006) Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry 67,1897-1906

[41] Haddock CK,Poston WSC,Dill PL,Foreyt JP,Ericsson M.Pharmacotherapy for Obesity: a quantitative analysis of four decades of published randomised clinical trials.Inst J Obes 2002;26:262-73

[42] Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial.. JAMA. 2003;2891820-5 PubMed

[43] Sturm R. Increases in clinically severe obesity in the United States, 1986-2000.. Arch Intern Med. 2003;1632146-8 PubMed

[44] Cooke D, Bloom S: The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 5:919–931, 2006

[45] Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 4:1083–1095, 2005

[46] Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ: Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 29:277–302,2006

[47] Medicines Control Agency statement on European legal action relating to anorectic agents. www.mca.gov.uk/whatsnew/whatsnew_2002.htm#2002

[48] General Medical Council. Good Medical Practice. London: GMC, 2001.

[49] Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ: Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 29:277–302,2006

[50] Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial..JAMA. 2003;2891820-5 PubMed

[51] Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Rouxen-Y- 500 patients: technique and results, with 3-60 month followup.. Obes Surg. 2000;10233-9 PubMed

[52] Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity.. Clin Ther. 1996;181006-35 PubMed

[53] Nguyen NT, Stevens CM, Wolfe BM. Incidence and outcome of anastomotic stricture after laparoscopic gastric bypass. J Gastrointest Surg. 2003;7:997-1003; discussion 1003.[PMID: 14675709]

[54] Samaha FF, Iqbal N, Seshadri P, Chicano KL, Daily DA, McGrory J. et al. A low- carbohydrate as compared with a lowfat dietin severe obesity.. N Engl JMed. 2003;3482074-81 PubMed

[55] National Institutes of Health(NIH),National Heart,Lung and Blood Institute(NLLBI).Clinical gidelines on the identification, evaluation and treatment of overweight and obesity: the evidence report.Washington: US Government Press,1998.

[56] Royal college of Physicians of London.Clinical management of overweight and obese patients with particular reference to the use of drugs.London:RCP,1998.

[57] Goldstein DJ. Beneficial health effects of modest weight loss..Int J ObesRelat Metab Disord 1992;16397-415 PubMed

[58] Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long- term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study.. Obes Res. 2001;9188- 95 PubMed

Untitled Page